Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2015

View Archived Issues

Inhibition of ADAM 8 decreases pancreatic tumor burden and metastasis

Analysis of SNPs associates cannabinoid dependence and depression

New solifenacin succinate oral formulation for pediatric use

University of Texas System patent describes new antineogenic agents

Zhejiang Medicine synthesizes Akt, PI3K and PDGFRbeta inhibitors

Arrien Pharmaceuticals reports development of retinoid RORgammaT receptor antagonists

Aeglea Biotherapeutics raises funds to develop enzyme therapies for metabolic diseases and cancer

Novel PET radiotracer provides direct measure of PKM2 expression in vivo

Genetech presents novel PAK 1 inhibitors

Hangzhou DAC Biotech reports development of novel tubulysin analogues

Glyxambi tablets now available in the U.S.

Cipher Pharmaceuticals acquires Canadian rights to novel treatment for psoriasis and RA

Karos Pharmaceuticals patents TPH1 inhibitors

Alios BioPharma develops new antiviral compounds

MEI Pharma reports topline data from randomized phase II study of pracinostat

Sirona Biochem reports data for SBM-TFC-837 for antiaging and regenerative medicine

Bristol-Myers Squibb and ZAI Lab enter licensing agreement to develop brivanib in China

Immunovaccine begins phase II trial of DPX-Survivac immunotherapy in lymphoma

Teikoku Pharma seeks FDA approval for non-alcohol formula of docetaxel

Opicapone shows safety and efficacy as an add-on to levodopa in PD patients

EMA grants orphan status to Kamada treatment for graft-versus-host disease

TB Alliance awarded Australian grant to advance STAND trial and other programs

Ascletis announces results of a phase II study with danoprevir for hepatitis C virus infection

EMA grants orphan drug designation to Reolysin for gynecological cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...